# Dajo Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dajo-bio

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Latest round: Seed (Aug 17, 2026)
- Investors on record: 3

## About

Based in Guangdong, China, and founded in 2025 by Qi Liu, Shenzhen Dajo Biopharmaceutical Co., Ltd., trading as Dajo Bio, operates in innovative drug research and development, targeting autoimmune diseases and solid tumors through precision immunotherapy technologies.
In August 2026, Dajo Bio raised a Seed funding from led by Liboshi Big Health, with participation from Nanshan SEI Investment and Summer Capital.
The company’s core products are next-generation TCR protein drug candidates supported by its proprietary FleXi-T affinity optimization platform, Full-Scanning safety assessment system, and T-Lock bispecific long-acting TCR platform.
The company primarily generates revenue from the research, development, and future commercialization of TCR-based therapeutic products and related biotechnology innovations.
The Seed funds raised will be primarily used to accelerate the iterative upgrades of the three independent innovative technology platforms and AI-TCR, and to expand and improve Daga's pipeline layout in the fields of autoimmune diseases and solid tumors. Following this round of financing, the company will comprehensively accelerate its R&D and industrialization processes, leveraging its first-mover advantage to aim for the top tier of the global TCR protein drug industry.

## Funding rounds

- Seed, Aug 17, 2026 — Summer Capital, Nanshan SEI Investment, Liboshi Big Health

## Investors

- Summer Capital — Seed
- Nanshan SEI Investment (https://capitalatlas.ai/funds/nanshan-sei-investment) — Seed
- Liboshi Big Health — Seed